MK-4716-001 Clinical Trial
Phase 1
250
about 5 years
18+
3 sites in NJ, TX, VA
What this study is about
This trial is testing a treatment called MK-4716 in people with certain solid tumors. Researchers are looking to see if this treatment is safe and well-tolerated when used alone or with other treatments.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Cetuximab
- 2.Receive Pembrolizumab
- 3.Take MK-4716
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cetuximab, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
injection (Injection), infusion
Primary: Number of Participants Who Discontinue Study Intervention Due to an AE, Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLT), Number of Participants Who Experience an Adverse Event (AE)
Secondary: Area Under the Concentration-Time Curve (AUC) of MK-4716, Half-Life (t1/2) of MK-4716, Maximum Plasma Concentration (Cmax) of MK-4716
Oncology